摘要
目的:观察黄连素对慢性萎缩性胃炎(CAG)病人的疗效以及对IL-6、IL-17表达的影响。方法:选择经胃镜检查符合CAG诊断的患者100例,随机分为治疗组和对照组,各50例。治疗组给予黄连素0.3 g 3次/d口服;对照组给予维酶素1.0 g 3次/d口服,疗程均为12周。观察治疗前后临床症状的变化,并复查胃镜及活检,进行组织病理学改善的评估;采用ELISA法测定血清白细胞介素6(IL-6)、白细胞介素17(IL-17)的表达量。结果:临床疗效比较,治疗组临床症状较对照组明显缓解,差异有统计学意义(P<0.05)。胃镜病例改善比较,治疗组胃黏膜病理改变较对照组明显改善,差异有统计学意义(P<0.05)。血清IL-6、IL-17的浓度比较,治疗组血清IL-6、IL-17的浓度均显著低于对照组,组间比较差异有统计学意义(P<0.05)。结论:黄连素能有效改善慢性萎缩性胃炎患者的临床症状和病理分级,其作用可能通过下调IL-6、IL-17的表达而实现。
Objective： To observe the clinical efficacy and the influence on interleukin 6（ IL- 6） and interleukin 17（ IL- 17） expressions of berberine in treatment of chronic atrophic gastritis（ CAG）. Methods： 100 patients diagnosed as CAG by endoscopy were randomly divided into treatment group and control group,50 cases in each. The treatment group were treated with berberine tablets,0. 3 g,3 / d orally and the control group was given dimension 1. 0g,3 / d orally. The course of treatment was 12 weeks. The changes of clinical symptoms were observed before and after treatment and we reviewed the gastroscopy and biopsy and histopathological improvement assessment. The expressions of IL- 6 and IL- 17 in serum were detected by ELISA. Results： Compared to the control group,clinical symptoms in treatment group were significantly alleviated and there was significant difference between two groups（ P〈 0. 05）. Compared to the control group,endoscopy pathology significantly improved in treatment group. The concentrations of serum IL- 6 and IL- 17 were significantly lower than those in the control group and there was statistically significant difference between two groups. Conclusion： Berberine can effectively improve the clinical symptoms and pathological grading in patients with CAG and the effect may be achieved through down- regulation of IL- 6 and IL- 17 expresssions.
出处
《中华中医药学刊》
CAS
北大核心
2015年第2期467-469,共3页
Chinese Archives of Traditional Chinese Medicine
